



## PRESS RELEASE

---

### ASLAN PHARMACEUTICALS AND ACT GENOMICS SIGN NEW COLLABORATION TO EXPLORE GENOMIC BACKGROUND TO THERAPEUTIC TREATMENT SUPER RESPONDERS

- *Studies aimed at understanding outlier patient populations to develop targeted oncology therapies*
- *Collaboration will initially explore major responses already observed in trials of ASLAN001*

**Singapore, 8 July, 2015** – ASLAN Pharmaceuticals (ASLAN), an oncology-focused biotechnology company, and ACT Genomics (ACT), a cancer molecular information services company, today announced a joint collaboration to perform detailed studies of the genomic background to extreme therapeutic responses, in which clinical trial patients show better than expected treatment response rates in certain instances.

ASLAN has an advanced portfolio of pathway inhibitors, immune checkpoint inhibitors and tumour metabolism stress molecules aimed at targeting Asia-prevalent tumour types including breast, gastric and bile duct cancers. Leveraging ACT's next generation sequencing and multiplex molecular testing platform, ASLAN will investigate several major responses demonstrated in clinical trials of the Company's lead development programme, ASLAN001, a potentially best-in-class small molecule pan-HER inhibitor, in breast cancer and cholangiocarcinoma (bile duct cancer). Specifically, in trials of ASLAN001 conducted in cholangiocarcinoma one patient showed 87% tumour shrinkage over a prolonged period of time, which is uncommon in this severe form of cancer.

**Commenting on the agreement, Dr. Bertil Lindmark, Chief Scientific Officer, ASLAN Pharmaceuticals said:** "We are very excited by the degree of clinical response we have seen in trials of ASLAN001 to date, and are looking forward to the opportunity to work with ACT Genomics to gain a greater understanding of the genomic background behind particular patients' super responses to certain treatments. The collaboration with ACT provides ASLAN with access to ground-breaking genomic expertise with the potential to transform cancer genomic information into precision diagnosis, improved cancer assays and, ultimately, better clinical outcomes for patients."

**Dr. Hua Chien Chen, Chief Executive Officer of ACT Genomics, added:** "Every patient's cancer is unique at the molecular level. The cancer molecular information is playing a critical role in patient stratification for clinical trials. We are pleased to work with ASLAN Pharmaceuticals to accelerate new targeted cancer drug development, all with the same goal of driving a transformation in cancer treatment."

**Ends**

#### Media contacts

<b>Emma Thompson / Stephanie Tan</b> Spurwing Communications Tel: +65 9107 5559 Email: <a href="mailto:ASLAN@spurwingcomms.com">ASLAN@spurwingcomms.com</a>	<b>Angus Wu, Vice Director, Business Development</b> ACT Genomics Tel: +886-227 953 660 Email: <a href="mailto:anguswu@actgenomics.com">anguswu@actgenomics.com</a>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



### **About ASLAN001**

ASLAN001 is a potent small molecule inhibitor of the HER-family of receptor tyrosine kinases (RTKs). The type I RTK family consists of four distinct but closely related receptors: epidermal growth factor receptor (EGFR, ErbB1, HER1), epidermal growth factor receptor 2 (HER2, ErbB2), epidermal growth factor receptor 3 (HER3, ErbB3), and epidermal growth factor receptor 4 (HER4, ErbB4). ASLAN001 is a potent, reversible inhibitor of EGFR, HER2 and HER4. In a large variety of cancers, the overexpression and/or constitutive activation of EGFR and HER2 are often observed and frequently correlate with poor clinical prognosis. Therefore, by inhibiting the activation of the HER receptors via ASLAN001, effects such as shrinkage of the tumor and longer survival can be anticipated. ASLAN001 is currently being studied in breast cancer and studies in gastric cancer and cholangiocarcinoma are underway.

### **About Cholangiocarcinoma**

Cholangiocarcinoma is cancer of the biliary tract and is currently classified into two subtypes - intrahepatic or extrahepatic. Globally, cholangiocarcinoma is the second most common form of liver cancer. Cholangiocarcinoma is a very heterogeneous and poorly understood disease for which there are currently no approved targeted therapies. There is strong scientific rationale for HER cMET and RON inhibitors in cholangiocarcinoma, demonstrating aberrant pathway activity with disease progression. ASLAN is currently planning further clinical trials of ASLAN001 in cholangiocarcinoma, targeting the HER, cMET and RON pathways.

### **About ASLAN Pharmaceuticals**

ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of high-value, differentiated clinical programmes. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Asia with a platform which reaches across the region via its offices in Singapore and Taiwan, enabling the Company to conduct and support regional clinical development programmes. The Company's proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN's most advanced compounds are in phase 2: ASLAN001, a pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002, which targets RON, an immune checkpoint inhibitor, and cMET.

[www.aslanpharma.com](http://www.aslanpharma.com)

### **About ACT Genomics**

ACT Genomics is a cancer molecular information service company with advanced high through-put sequencing platform, proprietary bioinformatics engines, and experience in drug discovery. Through accurate cancer genomic assays and comprehensive interpretation, ACT aims to transform cancer genomic information into precision diagnosis and personalized treatments. <http://en.actgenomics.com/>



## 亞獅康和行動基因簽署共同合作案以針對治療後腫瘤緩解病患進行基因研究

- 研究目標為深入瞭解特定病患族群，以發展腫瘤標靶治療
- 合作初期為探索ASLAN001臨床試驗中，病患出現的主要治療反應

### 2015年7月8日，新加坡

亞獅康股份有限公司（專精於抗癌藥物開發的生物科技公司）和行動基因（癌症分子資訊服務公司）於今日宣布共同合作案，針對臨床試驗病患呈現優於預期反應的案例，探究其基因表現。亞獅康公司先進的產品組合包括訊息傳遞路線抑制劑、免疫檢查點抑制劑和腫瘤代謝刺激分子，係針對亞洲較為盛行的癌症種類如乳癌、胃癌及膽管癌進行治療。憑藉行動基因的次世代定序和多重分子解析平台，亞獅康針對乳癌及膽管癌病患在ASLAN001臨床試驗中產生的治療反應進行深入研究。ASLAN001具有成為同級最佳小分子pan-HER抑制劑的潛力 - 在臨床試驗中有一位膽管癌的病患呈現腫瘤縮減87%，並維持相當長的一段時間，這在膽管癌這類嚴重的癌症中並不常見。

### 亞獅康首席科學長Dr. Bertil Lindmark針對合作案表示：

“ASLAN001迄今的研究，多個臨床實驗的反應令人十分興奮；期待有機會能和行動基因合作，以針對治療後腫瘤緩解病患的基因做更深入的了解。與行動基因的合作將帶給亞獅康對於基因研究突破性的了解，並可將癌症基因資訊進而轉化成精準治療，提高癌症檢測，最終提供病患更好的治療。”

### 行動基因執行長陳華鍵博士針對合作案表示：

“每個癌症病患的分子資訊是獨一無二的，癌症的分子資訊在臨床試驗上對於病患分群是十分關鍵的一環。我們很高興能與亞獅康合作並相信與其合作將加速癌症標靶藥物治療的發展，共同目標是提供嶄新的癌症治療。”

本文結束

### 媒體聯絡人

<b>Emma Thompson / Stephanie Tan</b> Spurwing Communications Tel: +65 9107 5559 Email: <a href="mailto:ASLAN@spurwingcomms.com">ASLAN@spurwingcomms.com</a>	<b>Angus Wu, Vice Director, Business Development</b> ACT Genomics Tel: +886-227 953 660 Email: <a href="mailto:anguswu@actgenomics.com">anguswu@actgenomics.com</a>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



### 關於ASLAN001

ASLAN001是HER家族的酪氨酸激酶受體（RTK）的強效小分子抑制劑。RTK家族包括四個不同但密切相關的受體：表皮生長因子受體（EGFR、ErbB1、HER1），表皮生長因子受體2（HER2、ErbB2），表皮生長因子受體3（HER3、ErbB3），和表皮生長因子受體4（HER4、ErbB4）。ASLAN001是EGFR、HER2和HER4的可逆性強效抑制劑。在許多種癌症經常發現EGFR與HER2過度表現或持續活化的現象，有這種現象的病人大多臨床癒後不佳；因此當ASLAN001抑制HER受體的活性，可預期腫瘤縮小並有更長的存活期。亞獅康進行中的研究包括乳癌、胃癌和膽管癌。

### 關於膽管癌

膽管癌為膽道腫瘤，分為兩種亞型－肝內及肝外膽管癌。以全球來看，膽管癌為肝癌中第二常見的癌別。膽管癌是一個多元性異常且對其了解甚少的疾病，目前並無核准的標靶治療。科學事證顯示HER、cMET和RON的異常與疾病惡化有關；因此亞獅康計畫以HER、cMET和RON為標靶，對ASLAN001進行更深入的膽管癌臨床試驗。

### 關於亞獅康

亞獅康股份有限公司為專精於抗癌藥物開發的生物科技公司，由經驗豐富的管理團隊及全球製藥專家帶領，持續專注於開發高價值的產品及具特色的臨床試驗。亞獅康總部設於亞洲，在新加坡及台灣的據點形成跨區域的平台，協助進行各區域臨床的開發研究。目前亞獅康有四項發展中的藥物，主要針對胃癌、乳癌及發炎性疾病。亞獅康目前已進入第二期的藥物：ASLAN001（pan-HER抑制劑），具有第二期胃癌試驗的數據；並同時發展膽管癌、乳癌及胃癌之治療；ASLAN002為RON（免疫檢查點）和cMET抑制劑。

欲獲得更多資訊，請參考[www.aslanpharma.com](http://www.aslanpharma.com)

### 關於行動基因

行動基因生物科技股份有限公司為癌症分子資訊公司，致力於提供先進的臨床癌症基因檢臨床醫藥資訊分析報告，以改善癌症治療品質並實踐癌症個人化治療。

欲獲得更多資訊，請參考<http://en.actgenomics.com>